SOPHiA GENETICS (NASDAQ:SOPH) Stock Price Crosses Above 50-Day Moving Average - Here's What Happened

Key Points

• SOPHiA GENETICS shares crossed above their 50-day moving average, trading as high as $7.91 and last at $7.86, compared with the average of $7.68.
• Analyst views are mixed: three analysts rate the stock Buy, one Hold, and one Sell. The consensus rating is Hold, with a $10 average price target.
• The company reported a quarterly loss of $0.24 per share, missing estimates of $0.20, while revenue of $24.27 million slightly exceeded expectations.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $7.68 and traded as high as $7.91. SOPHiA GENETICS shares last traded at $7.86, with a volume of 918,997 shares.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Thursday, October 15th. Zacks Research raised shares of SOPHiA GENETICS to a "hold" rating in a research report on Tuesday, July 21st. HC Wainwright reissued a "buy" rating and issued a $14.00 price target on shares of SOPHiA GENETICS in a report on Monday, October 12th. Finally, BTIG Research boosted their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, SOPHiA GENETICS presently has a consensus rating of "Hold" and a consensus target price of $10.00.

SOPHiA GENETICS Price Performance

The business has a 50-day simple moving average of $7.68 and a 200 day simple moving average of $6.01. The firm has a market cap of $659.38 million, a P/E ratio of -7.21 and a beta of 1.09. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.16 and a current ratio of 2.29.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.04). The business had revenue of $24.27 million during the quarter, compared to analysts' expectations of $24.03 million. SOPHiA GENETICS had a negative return on equity of 128.69% and a negative net margin of 89.18%. On average, analysts anticipate that SOPHiA GENETICS SA will post -0.94 earnings per share for the current fiscal year.

Insider Activity at SOPHiA GENETICS

In other SOPHiA GENETICS news, Director Kathy L. Hibbs sold 6,250 shares of the business's stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $8.68, for a total transaction of $54,250.00. Following the transaction, the director directly owned 103,242 shares of the company's stock, valued at approximately $896,140.56. The trade was a 5.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Philippe Menu sold 7,394 shares of the business's stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $8.13, for a total transaction of $60,113.22. Following the transaction, the insider owned 200,993 shares in the company, valued at $1,634,073.09. This represents a 3.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 157,162 shares of company stock valued at $1,270,334 over the last 90 days. Company insiders own 4.88% of the company's stock.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of institutional investors have recently added to or reduced their stakes in the company. Landscape Capital Management L.L.C. purchased a new stake in shares of SOPHiA GENETICS in the 3rd quarter worth approximately $1,030,000. Royce & Associates LP raised its stake in SOPHiA GENETICS by 15.0% during the third quarter. Royce & Associates LP now owns 3,887,743 shares of the company's stock valued at $32,579,000 after buying an additional 506,007 shares during the last quarter. Sowell Financial Services LLC purchased a new position in SOPHiA GENETICS during the third quarter valued at $2,865,000. Maven Securities LTD purchased a new position in SOPHiA GENETICS during the second quarter valued at $866,000. Finally, AXQ Capital LP bought a new stake in SOPHiA GENETICS in the second quarter worth $119,000. Institutional investors own 31.59% of the company's stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops data-analysis tools for genomics and other complex health data. Its cloud-based SOPHiA DDM platform uses artificial intelligence and analytics to help healthcare and research organizations interpret data and support clinical and scientific decision-making. The platform and related applications are used in areas including oncology, rare diseases and inherited conditions. The company serves hospitals, laboratories, biopharmaceutical companies and research organizations, with a presence across international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.